New biologic combo aims to tame rare lung fungal allergy
NCT ID NCT07362693
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether adding a biologic drug to standard treatment can reduce flare-ups in people with allergic bronchopulmonary aspergillosis (ABPA) and severe asthma. About 50 adults will receive a biologic for at least 4 months while continuing their usual asthma medications. Researchers will track how many acute attacks occur, hospitalizations, and steroid use to see if the biologic helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Biologic agents (e.g., monoclonal antibodies) added to standard asthma and ABPA therapy
- What this could lead to
- If successful, this could show that adding a biologic drug helps control ABPA and reduces severe asthma attacks, pointing toward a better management strategy.
- What could go wrong
- This is an observational study with only 50 participants, so results may not apply to everyone. Biologics can have side effects like allergic reactions or increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABPA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI model aims to predict dangerous lung Flare-Ups in ABPA patients
- Fungal fingerprints in lungs may predict ABPA Flare-Ups
- Brain aneurysm repair: Stent-Assisted coiling put to the test
- AI model aims to predict ABPA relapse risk
- Could a common Anti-Inflammatory pill boost biologic therapy for ulcerative colitis?
- BREATH study: tracking biologic drug effects in severe asthma